Galena Biopharma (GALE) is receiving a grant from the U.S. Department of Defense for a Phase II trial of the company's NeuVax treatment. The study will look at whether the therapy can prevent breast cancer from returning in high-risk HER2 3+ patients.
The study is due to start this year and will support Phase III and Phase IIb trials in 1+ and 2+ patients.
Galena's shares are +14%. (PR)